Pharmacokinetic analysis of venetoclax and treatment outcome in patients with acute myelogenous leukemia
Not Applicable
Recruiting
- Conditions
- acute myelogenous leukemia
- Registration Number
- JPRN-UMIN000047371
- Lead Sponsor
- Aiiku Hospital Blood Disorders Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1) Disagree with ICF. 2) Patients who lack medical adherence. 3) Patients who are otherwise considered ineligible for the study by the investigator.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To examine the relevance between the blood concentration of venetoclax and treatment response, such as CR rate and duration of response
- Secondary Outcome Measures
Name Time Method To examine the relevance between the blood concentration of venetoclax and adverse events (hematological AEs, tumor-lysis syndrome, infections)